Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib Desensitization for Kidney Transplant
NCT00908583Phase 4Completed
- Sponsor
- University of Cincinnati
- Start
- May 2009
- Primary completion
- Nov 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of bortezomib in Human Leukocyte Antigen Sensitization (5 arms), sponsored by University of Cincinnati. Primary endpoint: Number of Living Donor Transplant Candidates That Are Transplanted at 1 year. Started May 2009; status: completed.
02
Drugs
bortezomib
03
Conditions
Human Leukocyte Antigen Sensitization
Beyond the preview
Go deeper on NCT00908583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00908583.